Docetaxel enhances the cytotoxic effects of imatinib on Philadelphia positive human chronic myeloid leukemia cells

Hematology

Volumn 14, Issue 3, 2009, Pages 139-144

  Gucluler, Gozde ^a   Baran, Yusuf ^a  

^a IZMIR INSTITUTE OF TECHNOLOGY   (Turkey)

Author keywords

Apoptosis; BCR ABL; Chronic myeloid leukemia; Docetaxel; Imatinib

Indexed keywords

CASPASE 3; DOCETAXEL; IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RADIOSENSITIZING AGENT; TAXOID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL MEMBRANE; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; DRUG EFFECT; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEMBRANE POTENTIAL, MITOCHONDRIAL; PIPERAZINES; PYRIMIDINES; RADIATION-SENSITIZING AGENTS; TAXOIDS;

EID: 67949108168     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453309X426164     Document Type: Article

References (22)

1. Pant S, Chilukuri MP, Ramaswamy B. Docetaxel for the postsurgery treatment of patients with node-positive breast cancer. Ther Clin Risk Manag 2008; 4(2): 419-424.
2. Cao D, Bin Q, Ge Z, Yuan Y. Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett 2004; 214: 103-113.
3. Kim JC, Saha D, Cao Q, Choy H. Enhancement of radiation effects by combined docetaxel and flavopiridol treatment in lung cancer cells. Radiother Oncol 2004; 71(2): 213-221.
4. Volpe G, Panuzzo C, Ulisciani S, Cilloni D. Imatinib resistance in CML. Cancer Lett 2008; 274: 1-9.
5. Baran Y. Salas A, Senkal C et al. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem 2007; 282(15): 10922-10934.
6. Forrest DL, Trainor S, Brinkman RR et al. Cytogenetic and molecular responses to standart-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not through imatinib plasma levels. Leuk Res 2008; 33: 271-275.
7. Arunasree KM, Roy KR, Anilkumar K, Aparna A, Reddy GV, Reddanna P. Imatinib-resistant K562 cells are more sensitive to celecoxib a selective COX-2 inhibitor: role of COX-2 and MDR-1. Leuk Res 2008; 32(6): 855-864.
8. Chien JH, Tang JL, Chen RL, Li CC, Lee CP. Detection of BCRABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy. Leuk Res 2008; (32): 1724-1734.
9. Baran Y, Ural AU, Gunduz U. Mechanisms of cellular resistance to I ? matinib in human chronic myeloid leukemia cells. Hematology 2007; 12: 497-503.
10. Mathew P, Thall PF, Jones D et al. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 3323-3329. (Pubitemid 41103689)
11. Kim PS, Lee PP, Levy D. Dynamics and potential impact of the immuna response to chronic myelogenous leukemia. PLoS Comput Biol 2008; 4(6): E10000095.
12. Zembutsu H, Yanada M, Hishida A et al. Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Intl J Oncol 2007; 31: 313-322.
13. Lago LD, D'Hondt V, Awada A. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. The Oncologist 2008; 13: 845-858.
14. Comella P, Frasci G, Panza N et al. Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group. J Clin Oncol Vol 1999; 17(5): 1526-1534.
15. Gontarewicz A, Balabanov S, Keller G et al. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases. Leuk Res 2008; 32: 1857-1865.
16. Matei D, Emerson RE, Schilder J et al. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis. Cancer 2008; 113(4): 723-732.
17. Kancha RK, von Bubnoff N, Miething C, Peschel C, Gö tze KS, Justus D. Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation. Haematologica 2008; 93: 1718-1722.
18. Rö ssler J, Zambrzycka I, Lagodny J, Kontny U, Niemeyer CM. Effect of STI-571 (imatinib mesylate) in combination with retinoic acid and c-irradiation on viability of neuroblastoma cells. Bioch Biophys Com 2006; 342: 1405-1412.
19. Fabbri F, Brigliadori G, Carloni S et al. Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in hormone-sensitive prostate carcinoma cell line. J Trans Med 2008; 6: 43-53.
20. Di Lorenzo G, Figg WD, Fossa SD et al. Combination of bevacizumab and docetaxel-pretreated hormone-refractory cancer: a phase 2 study. Eur Ural 2008; 54: 1089-1096.
21. Navid F, Willert JR, McCarville MB et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 2008; 113(2): 419-425.
22. Boukovinas I, Souglakos J, Hatzidaki D et al. Docetaxel plus gemcitabine as fornt-line chemotherapy in elderly patients with lung adenocarcinomas: a multicenter phase II study, Lung Cancer 2008; 63: 77-82.